Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Priyanka Sreelatha"'
Publikováno v:
Journal of Clinical and Diagnostic Research, Vol 14, Iss 3, Pp XC09-XC12 (2020)
Introduction: Chemotherapy Induced Thrombocytopenia (CIT) is a common problem in clinical oncology. It leads to delay in administration of chemotherapy resulting in inferior outcomes. Timely administration of chemotherapy is necessary to ensure maxim
Externí odkaz:
https://doaj.org/article/c330ba260dbe425fb6006fc479a75f1d
Publikováno v:
Journal of Clinical and Diagnostic Research, Vol 12, Iss 3, Pp XD01-XD03 (2018)
Ewing’s sarcoma is an aggressive tumour of bone commonly affecting individuals in 10-20 years of age group. Older age and metastatic disease has an overall poor outcome. We are reporting a case of a 37-year-old lady with Ewing’s sarcoma who was i
Externí odkaz:
https://doaj.org/article/d6b757d6652c4cab819f5547ba24c6bc
Publikováno v:
Journal of Clinical and Diagnostic Research, Vol 14, Iss 3, Pp XC09-XC12 (2020)
Introduction: Chemotherapy Induced Thrombocytopenia (CIT) is a common problem in clinical oncology. It leads to delay in administration of chemotherapy resulting in inferior outcomes. Timely administration of chemotherapy is necessary to ensure maxim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef1b3dfa7d4914e4294c0dc908b74c57
https://doi.org/10.7860/jcdr/2020/42582.13560
https://doi.org/10.7860/jcdr/2020/42582.13560
Publikováno v:
Journal of Clinical and Diagnostic Research, Vol 12, Iss 3, Pp XD01-XD03 (2018)
Ewing’s sarcoma is an aggressive tumour of bone commonly affecting individuals in 10-20 years of age group. Older age and metastatic disease has an overall poor outcome. We are reporting a case of a 37-year-old lady with Ewing’s sarcoma who was i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d73b6d5f02d3675340032c093394bf42
https://doi.org/10.7860/jcdr/2018/31796.11298
https://doi.org/10.7860/jcdr/2018/31796.11298
Publikováno v:
National Journal of Physiology, Pharmacy and Pharmacology. 7:1
Sorafenib is an oral multikinase inhibitor used as a palliative intent for advanced hepatocellular carcinoma (HCC). Dermatologic toxicity is the main adverse effect limiting its use in many patients. However, Grade III dermatologic toxicity is rarely
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::630ae90a10f0a4c8da56c9245c5ecf01
https://doi.org/10.5455/njppp.2018.8.0725025072017
https://doi.org/10.5455/njppp.2018.8.0725025072017